Eubiotics Market Size, Share, and Growth Forecast 2026 - 2033

The global eubiotics market is expected to be valued at US$ 5.8 billion in 2026 and is projected to reach US$ 8.8 billion by 2033, growing at a CAGR of 6.2% between 2026 and 2033. The phase-out of antibiotic growth promoters in livestock production is the primary factor driving market growth. Animal feed producers are seeking alternatives to protect animal gut health and productivity. Regulations such as the European Union's ban on antibiotic growth promoters since 2006 and China's ban on growth-promoting antibiotics in feed from 2020 have made eubiotics a significant part of feed formulation.

Rising demand for animal protein is reinforcing this trend. The OECD-FAO Agricultural Outlook 2024–2033 projects global meat consumption to increase by about 12% by 2033. Growing consumer preference for antibiotic-free meat, expanding aquaculture, and advances in microbiome research are further supporting an estimated absolute dollar opportunity of US$ 3 billion through 2033.

Drivers - Regulatory Restrictions on Antibiotic Use in Livestock

Tightening restrictions on antibiotic use in animal feed are supporting eubiotics adoption. The European Union banned antibiotic growth promoters in 2006, while Regulation (EU) 2019/6 on veterinary medicinal products, applicable since January 2022, further restricted preventive antibiotic use in animal groups. The European Medicines Agency (EMA) reported that sales of veterinary antimicrobials across the EU and EEA declined by about 53% between 2011 and 2022.

In the U.S., the Food and Drug Administration (FDA) phased out growth-promotion uses of medically important antimicrobials through Guidance for Industry #213 in 2017 and brought remaining over-the-counter products under veterinary oversight through GFI #263 in 2023. China's Ministry of Agriculture and Rural Affairs (MARA), through Announcement No. 194, prohibited the use of growth-promoting antibiotics in feed from July 2020. These policies are encouraging livestock producers to adopt alternatives, including probiotics, organic acids, phytogenics, and enzymes, to support gut health and maintain productivity while reducing reliance on antibiotics.

Rising Global Demand for Animal Protein and Antibiotic-Free Meat

Growing consumption of meat, eggs, dairy, and seafood is increasing demand for feed additives that support animal health and productivity. The Food and Agriculture Organization (FAO) estimates that global meat production exceeds 360 million tons annually, while the OECD-FAO Agricultural Outlook identifies poultry as the largest contributor to projected growth in meat consumption. In the U.S., the U.S. Department of Agriculture (USDA) National Agricultural Statistics Service reports that more than 9 billion broilers are produced annually.

Consumer preference for antibiotic-free animal products is also influencing procurement practices, with retailers and restaurant chains adopting “raised without antibiotics” sourcing commitments. Producers reducing antibiotic use need effective strategies to manage intestinal health challenges, including necrotic enteritis and diarrhea, while maintaining feed efficiency. Eubiotics, including probiotics, prebiotics, organic acids, and phytogenics, are gaining attention as part of these strategies, supporting market growth alongside rising animal protein demand and changing sourcing requirements.

Variable Efficacy and Product Stability Challenges

Inconsistent field performance limits eubiotics adoption, particularly among cost-sensitive livestock producers. The effectiveness of probiotics, prebiotics, and phytogenics varies according to animal species, age, diet composition, farm hygiene, and disease pressure, making results less predictable across production systems. Some probiotic strains also lose viability during feed pelleting, where temperatures often reach 80–90°C, unless they are heat-tolerant, spore-forming, or protected through encapsulation.

Essential oils can be volatile and degrade during processing or storage if formulations are not adequately stabilized. Research published in journals such as Poultry Science and Animal Feed Science and Technology has reported variable outcomes across trials, reflecting differences in product composition and experimental conditions. Since feed represents a substantial share of livestock production costs, producers often assess additives based on measurable improvements in animal performance and economic returns. Uncertain results can therefore slow adoption, particularly in price-sensitive markets.

Complex Regulatory Approvals and High Development Costs

Regulatory requirements and product development costs create barriers for new eubiotic products. In the European Union, feed additives are authorized under Regulation (EC) No 1831/2003, with the European Food Safety Authority (EFSA) assessing safety and efficacy. Applicants need supporting evidence covering areas such as target animal safety, consumer safety, environmental impact, and product effectiveness, increasing the time and cost required to bring new products to market.

In the U.S., regulatory pathways depend on the ingredient, intended use, and product claims, with the FDA and the Association of American Feed Control Officials (AAFCO) playing different roles in ingredient oversight and feed regulation. New probiotic strains and botanical formulations require appropriate safety and regulatory assessments, adding to development costs for smaller companies. Differences in regulatory requirements across countries also complicate product registration and commercialization, potentially delaying international launches and limiting market access for innovative eubiotic solutions.

Opportunities – Phytogenics and Essential Oils Gaining Ground as Natural Alternatives

Phytogenic feed additives represent a promising growth opportunity through 2033. These plant-derived products include essential oils from oregano, thyme, and cinnamon, along with herbs, spices, and botanical extracts. Depending on their composition and application, they can support digestive function, influence intestinal microbial balance, and contribute to pathogen management. Their plant-based origin also aligns with demand for animal production systems that rely less on conventional antibiotics.

The EFSA has assessed numerous botanically defined flavoring compounds for use in animal feed, although authorization and permitted uses depend on the specific substance and application. The European Union's restriction on veterinary medicinal use of zinc oxide in piglets, effective from June 2022, has also encouraged interest in alternative approaches to managing post-weaning diarrhea, including organic acids and selected phytogenic products. Industry investment reinforces this opportunity: Cargill acquired phytogenic feed additive specialist Delacon in 2022. Continued research into mechanisms of action, product standardization, and species-specific formulations is expected to support adoption across poultry, swine, and aquaculture.

Expanding Aquaculture Creating New Demand for Gut-Health Solutions

Aquaculture expansion is creating additional opportunities for eubiotics suppliers. According to the FAO's State of World Fisheries and Aquaculture 2024 report, aquaculture production of aquatic animals reached 94.4 million tons in 2022, surpassing capture fisheries for the first time and accounting for about 51% of total aquatic animal production. Fish and shrimp farming operations face disease challenges, including vibriosis and early mortality syndrome, which can affect survival rates and production economics.

Concerns about antimicrobial resistance, residue compliance, and disease management are encouraging producers to explore alternatives to routine antibiotic use. Probiotics, organic acids, and phytogenics are being evaluated for their potential to support gut integrity, microbial balance, and disease resilience, with some products also targeting water quality. As aquaculture expands across Asia, Latin America, and Africa, demand for species-specific eubiotic formulations is expected to increase, creating growth opportunities within the aquafeed market.

Product Type Insights

Probiotics represent the leading product type, accounting for around 32% of the eubiotics market in 2026. Their leadership is supported by research on their role in maintaining gut microbiota balance, limiting pathogen colonization, and supporting nutrient utilization. Commonly used microorganisms include Bacillus subtilis, Bacillus licheniformis, Lactobacillus species, and Enterococcus faecium, although approved uses vary by strain and target animal.

Spore-forming Bacillus strains are widely used due to their relatively high stability during feed processing and storage. Probiotics also support intestinal health management in poultry, where Clostridium perfringens and associated necrotic enteritis remain important concerns following reductions in antibiotic growth promoter use.

Phytogenics and essential oils represent the fastest-growing product segment, driven by demand for natural feed additives, restrictions on certain conventional interventions such as medicinal zinc oxide use in Europe, and growing research into their antimicrobial, antioxidant, and digestive benefits. Continued development of standardized formulations is expected to support adoption across livestock production systems.

Livestock Insights

Poultry represents the leading livestock segment, accounting for about 45% of the market in 2026. Its position is supported by high global consumption, large-scale commercial production, short broiler production cycles, and the importance of feed conversion efficiency. The FAO reports that global poultry meat production exceeds 140 million tonnes annually, making poultry the largest category of meat production. Intensive production systems also increase the importance of managing intestinal health.

Restrictions on antibiotic growth promoters have encouraged producers to evaluate probiotics, organic acids, and phytogenics as part of broader strategies to maintain gut health and productivity. Large poultry producers in the U.S., Brazil, China, and the European Union are also responding to demand for reduced-antibiotic production systems.

Aquaculture is projected to be the fastest-growing livestock segment through 2033, driven by expanding fish and shrimp production, disease-management requirements, and efforts to reduce dependence on antibiotics. These factors are increasing interest in species-specific probiotics, organic acids, and other eubiotic solutions that support gut health and production performance.

Function Insights

Gut health represents the dominant function category, with an estimated 48% share in 2026. Its leading position is supported by the gastrointestinal tract's central role in digestion, nutrient absorption, immune function, and disease resistance. Eubiotics can help maintain microbial balance, support intestinal barrier function, and limit the establishment of certain pathogens, including Salmonella, E. coli, and Clostridium species, depending on the product and application. These benefits support efforts to improve feed efficiency and maintain animal performance, making gut health a key focus for livestock producers. Maintaining intestinal health can also contribute to food safety programs, although pathogen reduction depends on the intervention and wider farm management practices.

Immunity is projected to be the fastest-growing function segment from 2026 to 2033, driven by increasing demand for preventive animal health strategies, improved disease resilience, and reduced reliance on therapeutic antibiotics. Research into the effects of probiotics, prebiotics, and phytogenics on immune responses is also supporting product development for poultry, swine, and aquaculture applications.

North America Eubiotics Market Trends and Insights

North America is expected to lead the global eubiotics market with around 38% share in 2026. The region benefits from large-scale, integrated poultry, swine, and cattle production systems that rely on scientifically formulated feed and effective animal health management. FDA measures requiring veterinary oversight of medically important antimicrobials have strengthened interest in non-antibiotic gut health solutions. Key trends include the expansion of antibiotic-free and “no antibiotics ever” meat programs, increasing use of precision nutrition, and investment in microbiome research by feed manufacturers and academic institutions.

The strong presence of companies such as Cargill, ADM, Kemin Industries, Novus International, and Elanco supports product development and commercialization across the region. Canada's requirement for veterinary prescriptions for medically important antimicrobials, implemented in 2018, further encourages livestock producers to consider eubiotics as part of broader strategies to maintain gut health and productivity.

U.S. Eubiotics Market Size

The U.S. eubiotics market is estimated to reach US$ 1.9 billion in 2026. The country is a major producer of poultry, beef, and pork, with the USDA reporting annual broiler production exceeding nine billion birds. The FDA's 2023 summary report on antimicrobials sold or distributed for use in food-producing animals indicates that sales remain below their 2015 peak, reflecting changes in antimicrobial use and livestock production practices.

Retailer and restaurant-chain sourcing commitments are supporting demand for meat produced with reduced or no antibiotic use. Large livestock integrators are evaluating probiotics, organic acids, and phytogenics to support intestinal health and production efficiency, while university research is contributing to the evidence base for these products. Growing investment in aquaculture and the use of eubiotics in dairy and beef cattle feed also provide additional opportunities for suppliers through 2033.

Europe Eubiotics Market Trends and Insights

Europe is expected to account for a substantial share of the global eubiotics market in 2026, supported by established regulatory measures aimed at reducing antimicrobial use in livestock production. The EU Farm to Fork Strategy set a target of reducing overall EU sales of antimicrobials for farmed animals and aquaculture by 50% by 2030, relative to 2018. The restriction on veterinary medicinal use of zinc oxide in pigs, effective from June 2022, has also encouraged interest in alternative approaches to managing post-weaning diarrhea, including selected organic acids, probiotics, and phytogenics.

Key trends include the adoption of authorized feed additives, growing interest in sustainable livestock production, and demand for feed solutions that support animal health and resource efficiency. Companies such as DSM-Firmenich, BASF, Evonik, Novonesis, and Adisseo contribute to the region's research, product development, and supply capabilities. Rising feed costs and sustainability objectives are further encouraging producers to evaluate eubiotics that support feed conversion and help manage nutrient utilization.

Germany Eubiotics Market Insights

The Germany eubiotics market is estimated at US$ 325 million in 2026. Germany is a major European pork and poultry producer, supported by established livestock and feed manufacturing industries. The Federal Office of Consumer Protection and Food Safety (BVL) has reported a substantial decline in veterinary antibiotic sales since 2011. Germany's antibiotic minimization framework under the Medicinal Products Act also requires monitoring and benchmarking of antibiotic use in specified livestock operations.

These measures, alongside animal welfare requirements and the presence of companies such as BASF and Evonik, support demand for products that contribute to preventive animal health management. Quality assurance programs, including the QS scheme, also encourage attention to feed quality, animal health, and production standards. These factors are expected to support continued evaluation and adoption of eubiotics across German livestock operations through 2033.

U.K. Eubiotics Market Insights

The U.K. eubiotics market is expected to reach US$ 180 million in 2026. Reports from the Veterinary Medicines Directorate (VMD) indicate a substantial reduction in veterinary antibiotic sales for food-producing animals since 2014. Industry initiatives led by the Responsible Use of Medicines in Agriculture Alliance (RUMA) have also promoted responsible antimicrobial use across poultry, pig, cattle, and aquaculture production.

The country's farmed salmon industry, particularly in Scotland, provides an additional application area for eubiotics in aquafeed. Growing emphasis on sustainable farming, animal welfare, and responsible antibiotic use is expected to support demand for feed additives that help maintain gut health and production performance. Post-Brexit regulatory requirements for feed additives, including applicable authorization and market access procedures, also influence product availability and competition through 2033.

France Eubiotics Market Insights

The France eubiotics market is estimated at around US$ 260 million in 2026, accounting for roughly 16% of the European market. France is a major agricultural producer within the European Union, with substantial poultry, cattle, and pig production. National Ecoantibio initiatives, launched by the Ministry of Agriculture in 2012, have contributed to efforts to reduce veterinary antibiotic use. Data from the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) have documented progress in reducing antimicrobial exposure in animal production.

The Ecoantibio 3 plan for 2023–2028 continues to promote responsible antimicrobial use and the development of alternatives. Demand for differentiated animal products, including Label Rouge poultry, also supports producer attention to animal health and feeding practices. Feed manufacturers and agricultural cooperatives are evaluating organic acids, probiotics, and phytogenics as part of strategies to support gut health and production performance, creating opportunities for market growth through 2033.

Asia Pacific Eubiotics Market Trends and Insights

Asia Pacific is projected to be the fastest-growing regional market between 2026 and 2033, driven by rising animal protein consumption, expanding aquaculture, and tighter controls on antibiotic use in livestock production. China represents a major market due to its large pork industry, extensive feed production capacity, and commercial livestock operations. China's Ministry of Agriculture and Rural Affairs (MARA) prohibited the use of growth-promoting antibiotics in feed from July 2020, encouraging producers to consider alternative approaches to maintaining animal health and productivity.

Across the region, key trends include livestock farm modernization, the transition from small-scale to commercial production, expanding fish and shrimp farming, and growing awareness of antimicrobial resistance. International companies are strengthening local supply and research capabilities, while domestic manufacturers are developing cost-competitive eubiotic formulations. Rising disposable incomes, expanding modern retail channels, and increasing attention to food safety are further supporting demand for animal protein produced under responsible antimicrobial-use practices.

India Eubiotics Market Insights

The India eubiotics market is estimated at around US$ 140 million in 2026. India's 20th Livestock Census recorded approximately 852 million poultry birds, an increase of nearly 17% over the previous census, while the Department of Animal Husbandry and Dairying reports annual egg production exceeding 140 billion. India is also a major aquaculture producer, creating demand for feed solutions that support fish and shrimp health and productivity.

The government's 2019 prohibition on colistin use in food-producing animals, including its use in animal feed, and the National Action Plan on Antimicrobial Resistance have strengthened the focus on responsible antimicrobial use. Expanding commercial poultry and shrimp farming is creating opportunities for probiotics, organic acids, and phytogenics. Growth in organized feed mills and integrator-led broiler production, particularly in southern and western states, is expected to support wider eubiotics adoption through 2033.

The global eubiotics market is moderately consolidated, with leading companies such as DSM-Firmenich, Novonesis, Cargill, ADM, BASF SE, Evonik Industries, Kemin Industries, and Adisseo holding significant shares, alongside regional and specialty players. Market leaders differentiate through proprietary microbial strains, strong scientific trial data, regulatory approvals across multiple countries, and technical support services for feed mills and integrators. A major trend is consolidation, illustrated by the 2024 merger of Novozymes and Chr. Hansen to form Novonesis, combining enzyme and probiotic expertise.

Companies are also investing in microbiome research, precision fermentation, encapsulation technologies, and digital tools that link gut health data to farm performance. Partnerships with integrators and research universities, along with expansion of production facilities in Asia and Latin America, are central growth strategies.

Key Industry Developments

• February 2025: Novonesis agreed to acquire DSM-Firmenich's share of the Feed Enzyme Alliance for about EUR 1.5 billion, gaining full ownership of the joint feed enzyme business and strengthening its animal biosolutions portfolio.
• February 2024: DSM-Firmenich announced its plan to separate its Animal Nutrition & Health business, which includes eubiotic products, as part of a strategy to focus on nutrition, health, and beauty.
• January 2024: Novozymes and Chr. Hansen completed their merger, creating Novonesis, a global biosolutions company combining expertise in enzymes, probiotics, and microbial solutions for animal and human health.